"Biomedicines' Generative AI Pipeline Secures $273M in Series C Financing"
TL;DR Summary
Biotech startup Generate Biomedicines has raised $273 million in a Series C funding round, with investors including Amgen and NVIDIA. The company uses artificial intelligence and machine learning algorithms to identify new drugs, and has already launched its first clinical trial for a Covid monoclonal antibody. Generate Biomedicines plans to introduce 10 new drug candidates annually and has a total of 15 drug candidates in the works.
Topics:business#artificial-intelligence#biotech#biotechhealthcare#drug-discovery#funding#machine-learning
- Generate Biomedicines machine learning biotech raises $273M STAT
- Generate raises huge $273M series C, but it's also a down round FierceBiotech
- Generate:Biomedicines Announces Close of $273M Series C Financing to Advance Its Generative AI Pipeline of Preclinical and Clinical Protein Therapeutics Business Wire
- View Full Coverage on Google News
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
0 min
vs 1 min read
Condensed
49%
132 → 67 words
Want the full story? Read the original article
Read on STAT